By coinnews 
00:00 Speaker A
Roche, uh, drug maker, um, that has planned some investment in the US, talking about maybe some risks to that investment.
00:11 Speaker B
Yeah, this is based on that executive order that President Trump signed yesterday, looking at the most favored nations, or rather earlier this week, the most favored nations, which is focusing on reducing drug prices. Roche saying in a, uh, a comment to Bloomberg that if the proposed executive order goes into effect, their ability to fund investments that were previously announced, and they are referring to a $50 billion investment in manufacturing, uh, could be put in question. This is the first company to come out kind of against us and we weren’t kind of expecting this because the drug companies have made clear, big pharma has made clear that these huge announcements ranging up to 55 billion dollars, that that highest number from J&J, Eli Lilly also with about 50 billion in total. All of these announcements have been geared towards avoiding any other ongoing pressure including this most favored nations clause, including potential additional tariffs. We’ve also heard from AstraZeneca in a statement to us saying that it would, uh, this most favored nation clause would need a robust, uh, stakeholder investment and inclusion. So really trying to see what the industry does in light of all this additional pressure.